



**Universiteit
Leiden**
The Netherlands

Tailoring the tools to study prostate cancer metastasis

La Manna, F.

Citation

La Manna, F. (2021, October 14). *Tailoring the tools to study prostate cancer metastasis*. Retrieved from <https://hdl.handle.net/1887/3217101>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3217101>

Note: To cite this publication please use the final published version (if applicable).

Chapter 2

Metastases in Prostate Cancer

Metastases in Prostate Cancer

Federico La Manna^{1,3}, Sofia Karkampouna^{1,3}, Eugenio Zoni^{1,3}, Marta De Menna¹, Janine Hensel², George N. Thalmann¹ and Marianna Kruithof-de Julio¹

¹Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland

²Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, TX 77030 Houston, USA.

³equal contribution

Correspondence: marianna.kruithofdeljulio@dbmr.unibe.ch

Editors: Michael M. Shen and Mark A. Rubin

Cold Spring Harb Perspect Med, . 2019 Mar 1;9(3):a033688

<https://doi.org/10.1101/cshperspect.a033688>

Abstract

Prostate cancer prognosis and clinical outcome is directly dependent on metastatic occurrence. The bone microenvironment is a favourable metastatic niche. Different biological processes have been suggested to contribute to the osteotropism of prostate cancer, such as hemodynamics, bone-specific signaling interactions, and the “seed and soil” hypothesis. However, prevalence of disseminating tumor cells in the bone is not proportional to the actual occurrence of metastases, as not all patients will develop bone metastases. The fate and tumor-reforming ability of a metastatic cell is greatly influenced by the microenvironment.

In this chapter, the molecular mechanisms of bone- and soft tissue-metastasis in prostate cancer are discussed. Specific attention is dedicated to the residual disease, novel approaches and animal models employed in oncological translational research are illustrated.

1. Introduction

Prostate cancer (PCa) is the most common cancer and the second leading cause of cancer-associated death in men (Siegel et al. 2014). Due to the progress made in the treatment of the primary tumor, mortality in cancer patients is now increasingly linked to the metastatic disease (Sleeman and Steeg 2010)(**Figure 1**). PCa metastasizes to different organs with a propensity to bone (Gandaglia et al. 2013). Over 50 years ago more than 20% of patients presented with bone metastasis at diagnosis (Murphy et al. 1982). Data from older studies report median overall survival times of 30–36 months and a median overall survival of around 18 months in the castration-resistant setting, which in recent years has improved to a median overall survival of 42 months and 2-year overall survival of 72% (95% CI, 68–76) (James et al. 2015). Survival time was influenced by Performance status, age, Gleason score and metastasis distribution. Visceral involvement alone or with bone metastasis is a negative prognostic factor and should be considered a sign of a more aggressive disease in patients presenting with metastatic disease (Gandaglia et al. 2015). The spine, the pelvis and the ribs are the most frequently observed sites of bone metastasis (Torabian-Kakhki 2013). This distribution is often multifocal and the more frequent involvement of the axial skeleton suggests an affinity to the hematopoietic active red bone marrow. This is substantiated by the clinical observation that with extensive metastases to the axial skeleton, secondary (embryological) sites of hematopoiesis may be activated and may

become secondary sites of metastasis. Historically anatomical factors such as the venous Batson's plexus along the spine were thought to support this process (Batson 1940). The blood flow in the bone marrow of the adult human is about 2.5 L of blood per minute. Unlike other organs, the arterial supply of the bone marrow ends directly in large vessels (sinusoids). These are characterized by an endothelium allowing dynamic opening of pores within the endothelial cells themselves. The blood flow within the sinusoids is slow, in some areas almost stagnant. All these traits not only allow an easy egress of hematopoietic stem cells (HSCs) into the circulation, but also facilitate cancer cell extravasation and lodging in the bone marrow. However, the observation that sinusoids are also part of the spleen, which is not prone to be a metastatic site questions the exclusive role of the architecture of the bone marrow sinusoids in the osteotropism of PCa (Hensel and Thalmann 2016). Despite early detection of the primary tumor, bone metastases are detected in up to 10% of patients already at initial diagnosis of PCa. Additionally, 20-30% of the patients subjected to radical prostatectomy (RP) for organ-confined (stage T1-T3) PCa will relapse and fatally progress to advanced disease, where 70-80% of those patients will harbour bone metastases. Most




Figure 1. Overview of prostate cancer progression and therapeutic options. (A) Schematic drawing of different primary prostate cancer stages, as defined by T category of the TNM staging system. T1: confined, not palpable tumor; T2: confined, palpable tumor; T3: palpable tumor, grown through the prostate capsule and spreading to the neighboring tissues. (B) Diagram of prostate serum antigen (PSA) blood levels over cancer progression. PSA serum level is used as a diagnostic marker to monitor both the progression of the disease and the effectiveness of the treatments received by the patient.

likely, the majority of recurrences are due to disseminated tumor cells (DTCs or occult “micro- metastases”) that had already colonized the target tissue prior to the time of diagnosis and treatment of the primary tumor. This strongly suggests that in a significant proportion of early-diagnosed PCa the primary tumor already harbours cancer cells with stem-like cells properties (cancer stem-like cell, CSC-like) that are also able to colonize distant organs (metastasis initiating cells, MICs) (Valastyan and Weinberg 2011). Importantly, the microenvironment that harbours the metastatic site must be favourable to this colonization and potentially characterized by biological and molecular features that support the homing of malignant cells and their growth.

Metastasis is a highly inefficient process, in fact only 0.001-0.02% of DTC eventually colonize to distant organs resulting in tumor growth (Schneider et al. 2005; Luzzi et al. 1998). The metastatic process can be described as a multistep process that is initiated in the primary tumor and results in distant tumor growth. The first step is the acquisition of characteristics from a sessile/epithelial to a mesenchymal/invasive phenotype, described as epithelial-to-mesenchymal transition (EMT) which allows the cells to disseminate. This step of “de-differentiation” is crucial for the acquisition of invasive characteristics and for the dissemination of cancer cells from the primary tumor to the neighbouring and distant tissues. In order to form distant metastasis, the DTCs have to leave the primary site, survive in circulation, attach in the vasculature, migrate and colonize, go into dormancy and reactivate at the distant site. All this is facilitated by the permissive microenvironment. Much effort has been put into the understanding of these processes aiming to identify the best therapeutical window to target either the cancer cells, the microenvironment or both (Weilbaecher et al. 2011; Sterling et al. 2011).

2. Circulating and Disseminating tumor cells and the Metastatic Microenvironment

2.1 The seed and the soil hypothesis

Stephen Paget, more than 100 years ago observed in women autopsies, that “in cancer of breast the bones suffer in a special way” (Paget 1889). This landmark observation has led to the “seed and soil” hypothesis that postulates the reciprocal need of the seed (cancer cell) and the soil (microenvironment) so that metastasis can occur in distant individual organs. The uniqueness of

the microenvironment in the individual organs (liver, lung, bone, etc.) supports or opposes the colonization events that lead to the secondary tumor growth. The tumor cells that leave the primary site and enter circulation are defined as circulating tumor cells (CTCs); only a fraction of these cells has the capability to extravasate at a distant site and persist/survive as DTCs. Of these DTCs an even smaller fraction is capable of forming metastasis (Pantel and Speicher 2015; Yang and Weinberg 2008).

2.2 Two main models of metastasis

The first model hypothesizes that metastasis-initiating cells need to undergo deep molecular rearrangements in order to proceed through the various steps of the metastatic cascade and is often referred to as the “phenotypic plasticity model”. In order to leave the primary tumor site, cancer cells must undergo EMT. This process enables them to become more invasive and motile, allowing migration towards gradients of oxygen and nutrients brought by the vasculature associated to the tumor, often leaky, unorganized and incompletely formed. However, recent literature has pointed out that EMT might be a dispensable process for the occurrence of metastasis but fundamental for the acquisition of chemoresistance (Zheng et al. 2015).

The concept of “epithelial plasticity” being a process that requires somatic mutations and (epi)genetic changes exclusively in the cancer cells, is too simplistic. A fundamental contribution to the maintenance and to the progression of the primary tumor from a confined to an invasive state, is provided by different cell types and extracellular matrix components, which constitute the stroma (van der Pluijm 2011). It has been documented that cancer cells can “activate” different cellular components of the stroma, such as fibroblasts, and can recruit inflammatory, endothelial and mesenchymal cells. These cellular components can, in turn, support cancer cell proliferation and invasion (Mueller and Fusenig 2004; Bhowmick and Moses 2005). This combination of environmental factors and molecular properties on the tumor- and stromal-side, respectively, allows cancer cells to enter the bloodstream as CTCs (Carmeliet and Jain 2011). The controversy with this might be due to the notion of irreversibility of EMT (Thiery 2002) and the need of cancer cells, once they reached their metastatic site, to undergo mesenchymal-to-epithelial transition (MET) in order to regain their proliferative and metastatic behaviour. This would imply proteome and transcriptome changes that do not seem to be found in the DTCs of several cancers, which appear epithelial (Braun et al. 2000; Schardt et al. 2005; Dasgupta et al. 2017). Cancer cells with metastatic

potential would be required to show a high degree of epithelial-mesenchymal plasticity, in order to progress throughout the different stages of the metastatic spread. However, EMT-associated transcription factors have been shown by a number of groups to be associated with both positive and negative metastatic effects (Yang and Weinberg 2008; Ocaña et al. 2012; Tsai et al.; Vanharanta and Massagué 2013), leaving this a yet open question.

The second model hypothesizes the selection of subpopulations of cancer cells within the tumor that are genetically predisposed for metastasis: this model is frequently referred to as the “genetic” or “clonal model” (Ruiz et al. 2011; Nowell 1976). This model addressed the clinical observation that some metastases do not display a differentiated phenotype. According to this model, clones or subpopulations of tumor-initiating cells bear a set of genetic alterations that cause a permanent activation of EMT features that render them fit for the metastatic process. These genetic alterations could be either an intrinsic feature of these cancer subpopulations (driver mutations), developed during tumorigenesis (for instance when the tumorigenic alterations hit a cell early in its process of differentiation, like a tissue stem cell) or an acquired trait (passenger mutations), developed in response to environmental factors – like the selective pressure imposed by treatment with chemotherapeutic agents. Another interesting hypothesis comes from the observation that the CTCs can also be found in clusters. In this scenario, the cancer cells may facilitate their capability to dock and proliferate by taking with them their own “cancer soil” as passenger soil, as described for lung cancer (Duda et al. 2010) (**Figure 2**).

In the process of initial seeding, cell-cell interactions and cell adhesion to the extracellular matrix (ECM) play a critical role. The ECM of the growing cancer undergoes numerous alterations, in terms of both biochemical and physical properties (i.e. stiffness, elasticity and tension) (Miles and Sikes 2014). Integrins play a pivotal role in tumor progression, as they can couple ECM-derived mechanical cues with intracellular signalling pathways (Friedland et al. 2009). Metastatic prostate cancers show higher levels of active $\beta 1$ integrin, which confers both an enhanced capacity to colonize distant organs, through the adhesion to ECM molecules like fibronectin and collagen type I, and a survival advantage, through an increase in the resistance to anoikis - the programmed cell death induced by insufficient adhesion to the growth substrate (Lee et al. 2013) (Jin et al. 2014).

Cancer cells also express other integrins, like αv and $\beta 3$, that promote their adherence to a broader variety of proteins of the ECM of other organs, like osteopontin, thrombospondin, vitronectin, fibronectin, intracellular adhesion molecule (ICAM-1) and vascular adhesion molecule (VCAM-1) (Thalman et al.

1999) (Schneider et al. 2011) (Lu et al.; Zhao et al. 2007) that has led to the concept of "osteomimicry" by prostate cancer cells (Koenen et al. 1999). Prostate cancer cells also take advantage of the chemokine (C-X-C-motif) axis CXCL12/CXCR4 as homing mechanism to the bone, resulting in an enhanced capacity to contact the bone marrow niche and establish long-term dormancy. Among other compounds, prostate cancer cells secrete the chemokine CXCL16, which boosts the recruitment of bone marrow stromal cells (MSC). This signalling axis in turn promotes the conversion of MSC into cancer-associated fibroblasts (CAFs), which secrete high levels of CXCL12, that potentiates the EMT conversion of cancer cells and upregulates their expression of the cognate receptor CXCR4 (Jung et al. 2013). Cancer cells also upregulate the expression of matrix metalloproteases that facilitate extravasation/migration of the cancer cells (Sun et al. 2004). This process has been described for several cancer types and has therefore become an attractive target for therapeutical treatment of solid tumors (Schneider et al. 2011).

3. Residual disease and tumor dormancy

Once disseminated, cancer cells can survive as DTCs at the metastatic site for decades. The dynamics of metastatic outgrowth varies considerably between cells, cancer types, and individual patients. This survival can be defined either as a quiescent (dormant, or senescent) state or as an equilibrium, in which, although the disseminated metastatic foci will not grow to overt, clinically relevant metastases, they will still release cancerous cells into circulation (Ghajar 2015). Dormancy can in this regard be induced at a cellular level, in which case the cells undergo a G_0 - G_1 arrest, (Ghajar 2015; Aguirre-Ghiso 2007) or it can be induced at the population level as a cell-depleting event (e.g. apoptosis) (Sherwood et al. 1971; Aguirre-Ghiso 2007) (Gimbrone 1972; Rakhra et al. 2010).

This latter hypothesis is supported by the fact that CTCs can still be detected, for instance, in the circulation of breast cancer patients whose primary tumor had been removed and that do not present signs of relapse (Meng 2004; Ghajar 2015). CTCs have also been detected in the circulation of prostate cancer patients after radical prostatectomy, although correlation with patient clinical outcome is still controversial (Adsan et al. 2002; Thalgott et al. 2015; Morgan and Dearnaley 2014). Persistence of DTCs in the bone marrow of prostate cancer patients after radical prostatectomy, instead, is a predictor of recurrence (Morgan et al. 2009).

One key element that characterizes DTC growth dynamic and confers capacity to disseminate is the interaction with the microenvironment of the target organ and in particular with the local perivascular niches.




Figure 2. The metastatic spread of prostate cancer from the primary site.

The primary lesion growth is characterized by a dysregulation of the prostate architecture, inducing changes in the extracellular matrix (ECM) composition and architecture, together with the induction of an inflammatory state that activates stromal cells and favors the recruitment of blood vessels to the lesion. As the tumor recruits new blood vessels, the systemic dissemination of cancer cells (in the form of circulating tumor cells, or CTC) can take place. Two are the main models that explain the metastatic spread: "plasticity model" and the "clonal model". According to the plasticity model, as the cancer cells progress through malignancy, they may collect hits that make them fit for the metastatic process. The clonal model on the other hand theorizes that within the heterogeneous cancer cells subpopulations, clones with different fitness are generated, including some with the characteristics required for the metastatic spread. In addition, clusters of cells may form between spreading cancer cells and stromal cells from the primary lesion, the latter forming the "soil" cells that can facilitate the spreading and the survival of CTC. However, most of the CTCs will not survive in the bloodstream and will circulate as dead CTCs until clearance.

Given that cancer cells leave the primary site via the lymphatic or vascular site, it is not surprising that DTCs are found in the close proximity of the vascular basement membrane (Chambers et al. 2002; Ghajar et al. 2013; Kienast et al. 2010; Price et al. 2016). This particular microenvironment is defined as the perivascular niche and has a central role in normal tissue development and differentiation, by homing stem cells and maintaining them in a stem-like state through the balancing of pro- and anti-angiogenic factors (Butler et al. 2010; Christov et al. 2007; Goldman and Chen 2011; Xiao et al. 2013).

In prostate cancer, the main site of metastasis is the bone marrow (Bubendorf et al. 2000). The bone marrow is the main site of hematopoiesis in the adults, a process in which the long-term, life-long persistence of the hematopoietic stem cells (HSCs) is temporally associated with the high proliferative rates required to maintain hematological homeostasis (Mendelson and Frenette 2014; Calvi and Link 2015). Therefore, mechanisms must be present in the bone marrow to support both processes. Moreover, the bone marrow is also a site of intense cellular trafficking (Casanova-Acebes et al. 2013; Mazo et al. 2011; Méndez-Ferrer et al. 2008) and its peculiar vasculature structure has the characteristics that best allow this function (Nombela-Arrieta et al. 2013). It is then conceivable to hypothesize a correlation among the normal stem cell maintenance, the dormancy of the DTCs and the role of the perivascular niche. The "endosteal" (or "vascular") and the "perivascular" niche have both been described as the two major HSC niches. In the bone marrow, long-term repopulating HSC have been found both in the endosteal and in the perivascular space, two stem cell niches where HSC may reside in a state of quiescence that allows their long-term repopulating abilities and ensures protection against genotoxicity (Nombela-Arrieta et al. 2013) (Cheshier et al. 1999; Cheng 2000; Arai et al.; 2004). Interestingly bone marrow stromal cells have been shown to support and promote their fate by protecting them from oxidative stress and by limiting their entry into the cell cycle (Ludin et al. 2012). Prostate cancer cells compete with HSC for the occupancy of the limited niches in the bone marrow (Braun et al. 2005; Zhang et al. 2003) and reducing the niche size hampers dissemination (Shiozawa et al. 2011). However, once the DTCs have occupied ("hijacked") the vascular niche, they acquire a stem cell phenotype (Shiozawa et al. 2016). The acquired stem-like phenotype, together with the protective microenvironment in which prostate cancer DTCs reside, confers DTC an high degree of resistance to therapy (Chéry et al. 2014; Kobayashi et al. 2011). Of particular interest is the active role of a stable microvasculature on the initiation of the metastatic growth (Ghajar 2015). Once DTCs are awakened from their dormant state, they may start to reform macrometastases of osteoblastic or osteolytic nature depending on the origin

of primary tumor; prostate cancer leads to mainly osteoblastic lesions while breast to osteolytic (Logothetis and Lin 2005) (**Figure 3**). Tumor cells influence and are being influenced by the bone microenvironment, evading from the immune system and acquiring bone-related properties (osteomimicry, as previously mentioned) (Özdemir et al. 2014). The “preference” of tumor cells to colonize the bone has been attributed to a specific bone-related gene expression signature that tumor cells have prior to the metastasis, as it has been shown by studies in breast cancer (Kang et al. 2003). Additionally, cancer cells recruit bone marrow stromal cells to the primary site, where they become cancer-associated fibroblasts (CAFs), which contribute to the metastatic potential of malignant cells (Jung et al. 2013).

4. Bone metastasis: the vicious cycle

Osteoclast and osteoblasts mediate constantly the dynamic remodelling of the bone tissue. Tumor cells produce cytokines (e.g. tumor necrosis factor alpha (TNF- α), IL-11, VCAM-1, MMP1, Jagged1, parathyroid hormone-related protein (PTHrP)) that stimulate the osteoclast maturation or, indirectly, promote osteoclast differentiation by stimulating bone marrow osteoblast to produce IL-6 and RANKL. Bone matrix resorption releases then TGF- β and insulin-like growth factor-1 (IGF1), that promote proliferation and survival of the cancer cells, closing the circle to what is known as the “vicious cycle” that effectively promotes osteolytic metastasis (Weilbaecher et al. 2011; Ell et al. 2013). However, the employment of antiresorptive agents, like bisphosphonates, as strategy to inhibit bone resorption and interfere with bone metastasis revealed no effect on cancer cell proliferation in animal studies (Sasaki et al. 1995; van der Pluijm et al. 2005; Yuen et al. 2006). This suggests that other mechanisms, such as the coupling of angiogenesis and osteogenesis previously mentioned, support tumor cell growth in the bone. Interestingly, miRNA have recently also been reported to play a fundamental role in osteoclastogenesis. *Dicer1*, *Dgcr8*, and *Ago2* block osteoclast differentiation (Mizoguchi et al. 2010; Sugatani and Hruska 2009), whereas ectopic expression of miR-155 (Mann et al., 2010, Mizoguchi et al., 2010, Zhang et al., 2012) and repression of miR-21 (Sugatani et al. 2011) inhibit osteoclast differentiation. Recently, it has been shown that osteoclastogenesis is inhibited by that miR-133a, miR-141, and miR-219 whereas miR-190 might inhibit osteoclasts differentiation (Ell et al. 2013). Although bone lesions in prostate cancer are typically osteoblastic (Mundy 2002) (Logothetis and Lin

2005), the co-existence of osteoblastic and osteolytic response have been documented (Theriault 2012). Among the variety of factors that orchestrate




Figure 3. Dissemination of prostate cancer cells in the bone marrow: from DTCs to overt metastasis.

The hematopoietic bone tissue consists of two main parts: the bone tissue and the bone marrow. Bone is a highly regulated tissue that undergoes constant remodelling to keep its architecture and its mechanical properties; as osteoclasts resorb weak bone, skeletal stem cells undergo local expansion, followed by differentiation into osteoblasts. Depending on the local microenvironment and the tissue architecture, osteoblasts will further differentiate either into bone-producing osteocyte or into bone-lining cells, namely the layer of cells that is in contact with the marrow cavities, where hematopoiesis occurs. In order to ensure the life-long production of blood, hematopoietic stem cells (HSC) reside in specific areas, or niches, supported by specialized stromal cells (or niche cells) and that can be found both at the endosteal side and at the perivascular side of the bone marrow. Within these niches, HSC are induced in a state of quiescence, protected from cellular stresses and prevented from further proliferation. Prostate CTCs may disseminate to the bone marrow and compete with the HSC for the space in the niches. Within the niches, DTC could remain dormant for an indefinite amount of time. Eventually, DTCs may exit their dormant state and start proliferating, bending the coupled processes of bone resorption and bone formation to support their growth. Most frequently, this vicious cycle produces hyperplastic bone tissue, eventually forming clinically relevant osteosclerotic metastasis.

the balance between osteoclastic- and osteoblastic-activity, TGF- β and Wnt signalling are two fundamental networks that regulate the maintenance and expansion of osteoprogenitor cells and their differentiation towards osteoblasts.

The canonical Wnt signaling pathway seems to play a role in the onset of castration resistance in prostate cancer (Wang et al. 2008). Moreover, alterations of canonical Wnt signaling, such as modulation of the the *dickkopf* (DKK) genes or mutations of sclerostin (SOST), which inhibits LRP5, contribute to disrupt bone formation, a process where Wnt signaling exerts a crucial role (Semenov et al. 2005).

Wnt signaling also induces the expression of osteoprotegerin (OPG), which prevents the binding of Receptor Activator of Nuclear Factor κ B (RANKL) to RANK, thereby inhibiting osteoclast function and leading to a "bone active effect" (Rentsch et al. 2009) The TGF- β superfamily also exerts a major role in the context of the bone microenvironment and its remodelling in PCa. TGF- β supports the development of bone metastasis from PCa in animal models (Fournier et al. 2015). In particular, bone morphogenetic proteins (BMPs) and Noggin, which antagonizes BMP signaling, are functionally involved in skeletal and joints morphogenesis, bone remodeling and in different cellular processes including osteogenesis (Chen et al. 2004). One of the main BMPs involved in the recruitment of osteoblasts is represent by BMP6 (Dai et al. 2005). On the other hand, the recruitment of osteoclasts and the stimulation of their activity in prostate cancer is mediated by MMP-7, which cleaves RANKL (thereby stimulating osteoclastogenesis (Lynch et al. 2005)) and Noggin, which antagonizes BMPs and impairs bone formation (Schwaninger et al. 2007; Secondini et al. 2011).

5. Soft tissue metastasis

The common paradigm of tumor progression is that tumor cells from an advanced tumor unidirectionally migrate to lymphatic sites and then towards distant organs to form secondary metastases (Halsted 1894). This view has been challenged by recent studies showing that tumor cells can, at any point of tumor formation, multidirectionally seed to distant organs, while secondary and tertiary metastases can form independently from the primary clone (Haffner et al. 2013; Beltran et al. 2016). Presence of lymph node (LN) metastases is a frequent consequence of PCa associated with high risk, poorer outcome and limited therapeutic possibilities, such as surgical resection of pelvic LN, radiotherapy and androgen deprivation therapy (ADT). Surgical

resection may not be effective in removing all LN metastases due to imaging and detection limitations, while multiple surgeries are not an option due to postoperative scarring and other complications (Sankineni et al. 2015). Disease-free survival is directly dependent on LN staging and number of metastases. The frequency of mitochondrial mutations, affecting the metabolism of tumor cells, is lower in LN, liver and lung metastases compared to bone metastases (Arnold et al. 2015). Visceral metastases in men with metastatic, castration-resistant prostate cancer (CRPC) constitute a high prevalence and are linked to poor outcomes (Halabi et al. 2014). B-cell lymphoma 2 (BCL-2), BCL-XL, myeloid cell leukemia 1 (MCL-1) and survivin expression has been measured in primary prostate cancers and in small cohorts of lymph node and bone metastases (Zellweger et al. 2005; Krajewska et al. 2003). Their expression has been associated with transgression of the prostate capsule, risk of relapse and metastatic progression (Scherr et al. 1999). Interestingly, soft tissue metastasis transcriptional and protein profile differs from that of bone metastasis. In particular, nuclear survivin was observed in soft tissue metastasis whereas bone metastases exhibit relative overexpression of cytoplasmatic survivin, suggesting that cancer cell apoptosis-inducing drugs may exert various effects and may show very different efficacies depending on the site of the metastasis. Additionally, in liver and LN tissues, the angiogenic expression profile was different (Morrissey et al. 2008) suggesting that factors involved in tumor vascular recruitment and maintenance may also be affected by the microenvironment.

PCa adenocarcinomas show osteotropism, resulting in osteoblastic and osteolytic lesions, however, neuroendocrine (NE) tumors metastasize prevalently to visceral sites (Marcus et al. 2012). NE cases, both the spontaneous ones and those arising following ADT therapy, are associated with low PSA values, visceral metastases and poor survival (Palmgren et al. 2007).

The mechanisms of different organotropic properties of various PCa types remain to be elucidated.

6. Experimental models of bone metastasis

With the increasing life expectancy of men, PCa has become a major-medical problem. Once the tumor has metastasized, outcome is dismal. Research on prostate cancer bone metastases has been hampered by the limited number of experimental models available.

The reasons for this are multiple: poor growth potential of human prostate tumor tissue in nude mice; slow development of immune deficient mice strains; limited cell lines; lack of spontaneous prostate cancer in animals with the exception of ACI/Seg and Lobund-Wistar rats. With the advent of mutant nude mice with a deficient cell-mediated immune response and only slightly impaired humoral antibody formation, xenografts of cell lines and human tumor tissue became possible and opened a new era of research (van Weerden and Romijn 2000), albeit still impeded by an increased natural killer (NK) cell activity in these animals. A number of preclinical models using state-of-the-art molecular imaging for cell tracking and drug response have been developed (Buijs et al. 2007; van den Hoogen et al. 2010; Eaton et al. 2010). Cancer cell tracking and drug response can be studied by intracardiac delivery of human PCa cells that stably express either bioluminescence (e.g. luciferase) or fluorescence (e.g. NIRF proteins or GFP) reporters as a model of bone metastasis. Orthotopic and intraosseous cell delivery models are used for the study of primary PCa and metastatic PCa and in particular of the interactions between cancer cells and bone microenvironment (Dai et al. 2016).

Several efforts to obtain xenografts from patient samples (patient-derived xenografts, PDX) have been attempted. The model PC-82 was the first androgen-dependent PCa xenograft established, achieving a success rate of about 5% over many years (Hoehn et al. 1980) (van Weerden and Romijn 2000). *In vivo* growth rate was improved by the introduction of Matrigel where cells were suspended and mixed with Matrigel, allowing the propagation of the CWR tumor series (Pretlow et al. 1991). Seven additional xenograft models were established in BALB/c mice using intact tumor piece implantation and testosterone administration, from primary and metastatic PCa (LN and skin) (van Weerden et al. 1996). Bone and LN metastasis-derived PCa xenografts were developed by co-injection of tumor cells with Matrigel in severe combined immunodeficient (SCID) mice (Klein et al. 1997). The bone metastasis-derived LAPC-9 model is dependent on androgens for growth, secretes PSA and shows spontaneous tumor reinitiation after prolonged androgen deprivation (Craft et al. 1999). Another model (Garcia et al. 2014) that has been used to study the transition from androgen-dependent to androgen-resistant tumor growth is the LN metastasis-derived LAPC-4 model, established by the same group (Craft et al. 1999).

The BM18 PCa xenograft model, developed from a bone metastasis biopsy, retains androgen-dependent growth and survival properties, while it recapitulates the luminal phenotype observed in human PCa with stem cell characteristics similar to those of castration-resistant NKX3.1 cells (CARNs) described in the mouse (Germann et al. 2012; Wang et al. 2009). Similar results

were also achieved in the the LuCaP model (Ellis et al. 1996) and the MDA model (Navone et al. 1997).

Taking into account the importance of stromal-epithelial interactions in tumor development and progression, a cell-cell recombination model was generated by the coinoculation of non-tumorigenic LNCaP cells (Horoszewicz et al. 1983) with organ-specific fibroblasts from the bone into athymic nude mice, showing the ability to form solid tumors (Gleave et al. 1991). By altering the stromal and hormonal environment *in vivo*, an androgen-independent, tumorigenic LNCaP subline, C4-2, capable of growing tumors in the castrated host was derived. C4-2 cells secrete PSA autonomously and metastasize to the LN and to the bone with an incidence of 11-50%, while exhibiting a higher incidence of axial skeleton metastases in castrated hosts. From C4-2 osseous metastases, several cell lines were isolated and denoted as B2, B3, B4, and B5 (Thalmann et al. 2000).

In recent years, several genetically engineered mouse models (GEMMs) of prostate cancer have been established that recapitulate the stages of PCa development, from PIN lesions to localised and invasive adenocarcinoma, to LN metastasis. Telomerase reactivation in the Prostate-specific probasin (PB) promoter-driven Smad4 conditional knockout, p53/Pten double null model (PB-p53/Pten) leads to prostate tumors that progress to bone metastases (Ding et al. 2012).

However, there are limited GEMMs models that progress to bone metastases (Grabowska et al. 2014) which can provide insight on the mechanisms of human PCa metastatic cues.

7. Bone metastases in the clinic

Metastatic PCa remains an important clinical problem given the growing number of men with advanced disease, its impact on the quality of life and ultimately, as a cause of mortality. Osteoblastic bone lesions to the axial skeleton are the most common metastasis in men with advanced prostate cancer. Palliative treatment is a priority, with the goals of relieving pain, improving mobility, and preventing complications such as pathologic fractures or epidural cord compression.

ADT remains the treatment for metastatic PCa, and while this reduces the symptoms and tumor growth, recurrence of CRPC is almost certain. Histopathology of end-stage bone metastases acquired at autopsy or as a result of surgical resections for spinal cord compressions or pathological fractures (Maitland and Collins 2008; Collins et al. 2005) has shown that bone

metastases are heterogeneous, even within a single patient. Importantly, although nuclear androgen receptor (AR) staining is usually prominent in most cells, non-neuroendocrine, AR-negative tumor cells are clearly observed in both CRPC and treatment-naïve metastasis (Colombel et al. 2012). These findings imply that AR-independent cell survival in the bone microenvironment occurs, and the mechanisms contributing to such survival are of great interest. The heterogeneity of metastatic disease suggests that second generation, AR-directed therapies such as abiraterone and enzalutamide most likely will need to be complemented by therapies directed against non-AR pathways and bone-targeting therapies.

ADT increases bone resorption, reduces mineral density and increases risk of fracture thus indirectly leading to occurrence of bone metastasis in CRPC patients (Ottewell et al. 2014). Bisphosphonates have been shown to prevent bone loss associated with ADT however a positive effect on fracture prevention is lacking. Bisphosphonates aside current treatments of bone metastases include surgery, bone-targeted radiopharmaceuticals, and denosumab.

Denosumab is an FDA-approved humanized monoclonal antibody that binds to RANKL, a key factor in the pathway for osteoclast formation and activation, as previously discussed. ADT patients treated with Denosumab showed increased bone mineral density and reduction in vertebral fractures (Smith et al. 2009).

Currently, the only FDA-approved bone-targeting radioisotopes for patients with symptomatic metastatic CRPC are Strontium-89 chloride (Sr-89) and Samarium-153 lexidronam (Sm-153). Both have been shown through multiple clinical trials to be effective agents for bone pain palliation. Radium-223 chloride (Ra-223) is the first radiopharmaceutical drug to demonstrate a prolongation of overall survival in these patients and palliative benefits (Goyal and Antonarakis 2012).

Acknowledgments

The authors acknowledge somersault18:24 BVBA for drawing the figures.

References

- Adsan Ö, Cecchini MG, Bisoffi M, Wetterwald A, Klima I, Danuser HJ, Studer UE, Thalmann GN. 2002. Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence? *BJU international* **90**: 579–585.
- Aguirre-Ghiso JA. 2007. Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer* **7**: 834–846.
- Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche. *Cell* **118**: 149–161.
- Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. 2004. Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche. *Cell* **118**: 149–161.
- Arnold RS, Fedewa SA, Goodman M, Osunkoya AO, Kissick HT, Morrissey C, True LD, Petros JA. 2015. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. *Bone* **78**: 81–86.
- Batson OV. 1940. The function of the vertebral veins and their rôle in the spread of metastases. *Annals of Surgery* **112**: 138–149.
- Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, et al. 2016. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nat Med* **22**: 298–305.
- Bhowmick NA, Moses HL. 2005. Tumor–stroma interactions. *Oncogenes and cell proliferation* **15**: 97–101.
- Braun S, Pantel K, Muller P, Janni W, Hepp F, Kantenich CRM, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, et al. 2000. Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer. *N Engl J Med* **342**: 525–533.
- Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, et al. 2005. A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer. *N Engl J Med* **353**: 793–802.
- Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. 2000. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. *Human pathology* **31**: 578–583.
- Buijs JT, Rentsch CA, van der Horst G, van Overveld PGM, Wetterwald A, Schwaninger R, Henriquez NV, Dijke Ten P, Borovecki F, Markwalder R, et al. 2007. BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo. *Am J Pathol* **171**: 1047–1057.
- Butler JM, Kobayashi H, Rafii S. 2010. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. *Nat Rev Cancer* **10**: 138–146.
- Calvi LM, Link DC. 2015. The hematopoietic stem cell niche in homeostasis and disease. *Blood* **126**: 2443–2451.
- Carmeliet P, Jain RK. 2011. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov* **10**: 417–427.
- Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chèvre R, A-González N, Kunisaki Y, Zhang D, van Rooijen N, Silberstein LE, et al. 2013. Rhythmic Modulation of the Hematopoietic Niche through Neutrophil Clearance. *Cell* **153**: 1025–1035.
- Chambers AF, Groom AC, MacDonald IC. 2002. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer* **2**: 563–572.
- Chen D, Zhao M, Mundy GR. 2004. Bone morphogenetic proteins. *Growth Factors* **22**: 233–241.
- Cheng T. 2000. Hematopoietic Stem Cell Quiescence Maintained by p21cip1/waf1. *Science* **287**: 1804–1808.
- Cheshier SH, Morrison SJ, Liao X, Weissman IL. 1999. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proceedings of the National Academy of Sciences* **96**: 3120–3125.
- Chéry L, Lam H-M, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, et al. 2014. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. *Oncotarget* **5**: 9939–9951.
- Christov C, Chretien F, Abou-Khalil R, Bassez G, Vallet G, Authier FJ, Bassaglia Y, Shinin V, Tajbakhsh S, Chazaud B, et al. 2007. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. *Mol Biol Cell* **18**: 1397–1409.
- Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. 2005. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Research* **65**: 10946–10951.
- Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clézardin P, Thalmann G. 2012. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. *The Prostate* **72**: 713–720.
- Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. *Nature medicine* **5**: 280–285.

Metastases in Prostate Cancer

- Dai J, Hensel J, Wang N, Kruihof-de Julio M, Shiozawa Y. 2016. Mouse models for studying prostate cancer bone metastasis. *Bonekey Rep* **5**: 777.
- Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. 2005. Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism. *Cancer Research* **65**: 8274–8285.
- Dasgupta A, Lim AR, Ghajar CM. 2017. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? *Molecular oncology* **11**: 40–61.
- Ding Z, Wu C-J, Jaskieloff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, et al. 2012. Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases. *Cell* **148**: 896–907.
- Duda DG, Duyverman AMMJ, Kohno M, Snuderl M, Steller EJA, Fukumura D, Jain RK. 2010. Malignant cells facilitate lung metastasis by bringing their own soil. *Proceedings of the National Academy of Sciences* **107**: 21677–21682.
- Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalmann G. 2010. Evaluation of the Frequency of Putative Prostate Cancer Stem Cells in Primary and Metastatic Prostate Cancer. *The Prostate* **70**: 875–882.
- Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y. 2013. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. *Cancer Cell* **24**: 542–556.
- Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. 1996. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. *Clin Cancer Res* **2**: 1039–1048.
- Fournier PGJ, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, et al. 2015. The TGF- β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. *Cancer Cell* **27**: 809–821.
- Friedland JC, Lee MH, Boettiger D. 2009. Mechanically Activated Integrin Switch Controls 5 1 Function. *Science* **323**: 642–644.
- Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh Q-D, et al. 2013. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *The Prostate* **74**: 210–216.
- Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M. 2015. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. *European urology* **68**: 325–334.
- Garcia RR, Masoodi KZ, Pascal LE, Nelson JB, Wang Z. 2014. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5 α -reductase inhibitor dutasteride. *Am J Clin Exp Urol* **2**: 82–91.
- Germann M, Wetterwald A, Guzmán-Ramírez N, van der Pluijm G, Culig Z, Cecchini MG, Williams ED, Thalmann GN. 2012. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. *Stem cells (Dayton, Ohio)* **30**: 1076–1086.
- Ghajar CM. 2015. Metastasis prevention by targeting the dormant niche. *Nat Rev Cancer* **15**: 238–247.
- Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajar KA, Stainier DY, et al. 2013. The perivascular niche regulates breast tumour dormancy. *Nat Cell Biol* **15**: 807–817.
- Gimbrone MA. 1972. Tumor dormancy in vivo by prevention of neovascularization. *The Journal of experimental medicine* **136**: 261–276.
- Gleave M, Hsieh JT, Gao CA, Eschenbach von AC, Chung LW. 1991. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. *Cancer Research* **51**: 3753–3761.
- Goldman SA, Chen Z. 2011. Perivascular instruction of cell genesis and fate in the adult brain. *Nat Neurosci* **14**: 1382–1389.
- Goyal J, Antonarakis ES. 2012. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. *Cancer letters* **323**: 135–146.
- Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ. 2014. Mouse Models of Prostate Cancer: Picking the Best Model for the Question. *Cancer metastasis reviews* **33**: 377–397.
- Haffner MC, Mosbrugger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gurel M, Hicks J, Meeker AK, et al. 2013. Tracking the clonal origin of lethal prostate cancer. *J Clin Invest* **123**: 4918–4922.
- Halabi S, Kelly WK, Zhou H, Armstrong AJ, Quinn D, Fizazi K, Solomon NC, Tannock I, Petrylak DP, Morris MJ, et al. 2014. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. *JCO* **32**: 5002–5002.
- Halsted WS. 1894. I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. *Annals of Surgery* **20**: 497–555.
- Hensel J, Thalmann GN. 2016. Biology of Bone Metastases in Prostate Cancer. *Urology* **92** **15** -: 6–13.
- Hoehn W, Schroeder FH, Reimann JF, Joebsis AC, Hermanek P. 1980. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82). *The Prostate* **1**: 95–104.

- Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. 1983. LNCaP model of human prostatic carcinoma. *Cancer Research* **43**: 1809–1818.
- James ND, Spears MR, Clarke NW, Dearnaley DP, de Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, et al. 2015. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). *European urology* **67**: 1028–1038.
- Jin J-K, Tien P-C, Cheng C-J, Song JH, Huang C, Lin SH, Gallick GE. 2014. Talin1 phosphorylation activates $\beta 1$ integrins: a novel mechanism to promote prostate cancer bone metastasis. *Oncogene* **34**: 1811–1821.
- Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, et al. 2013. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. *Nature Communications* **4**: 1795.
- Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massagué J. 2003. A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell* **3**: 537–549.
- Kienast Y, Baumgarten von L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F. 2010. Real-time imaging reveals the single steps of brain metastasis formation. *Nat Med* **16**: 116–122.
- Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, et al. 1997. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. *Nature medicine* **3**: 402–408.
- Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, Pai SK, Liu W, Fukuda K, Chambers C, et al. 2011. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. *The Journal of experimental medicine* **208**: 2641–2655.
- Koenenman KS, Yeung F, Chung LWK. 1999. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. *The Prostate* **39**: 246–261.
- Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, et al. 2003. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. *Clin Cancer Res* **9**: 4914–4925.
- Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. 1996. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. *Am J Pathol* **148**: 1567–1576.
- Lee YC, Jin J-K, Cheng C-J, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, et al. 2013. Targeting Constitutively Activated 1 Integrins Inhibits Prostate Cancer Metastasis. *Molecular Cancer Research* **11**: 405–417.
- Logothetis CJ, Lin SH. 2005. Osteoblasts in prostate cancer metastasis to bone. *Nat Rev Cancer* **5**: 21–28.
- Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, et al. VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging $\alpha 4\beta 1$ -Positive Osteoclast Progenitors. *Cancer Cell* **20**: 701–714.
- Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, et al. VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging $\alpha 4\beta 1$ -Positive Osteoclast Progenitors. *Cancer Cell* **20**: 701–714.
- Ludin A, Itkin T, Gur-Cohen S, Mildner A, Shezen E, Golan K, Kollet O, Kalinkovich A, Porat Z, D'Uva G, et al. 2012. Monocytes-macrophages that express α -smooth muscle actin preserve primitive hematopoietic cells in the bone marrow. *Nat Immunol* **13**: 1072–1082.
- Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. 1998. Multistep Nature of Metastatic Inefficiency. *Am J Pathol* **153**: 865–873.
- Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, et al. 2005. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. *Cancer Cell* **7**: 485–496.
- Maitland NJ, Collins AT. 2008. Prostate cancer stem cells: a new target for therapy. *J Clin Oncol* **26**: 2862–2870.
- Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. 2012. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. *Prostate Cancer Prostatic Dis* **15**: 283–288.
- Mazo IB, Massberg S, Andrian von UH. 2011. Hematopoietic stem and progenitor cell trafficking. *Trends in immunology* **32**: 493–503.
- Mendelson A, Frenette PS. 2014. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. *Nature medicine* **20**: 833–846.
- Meng S. 2004. Circulating Tumor Cells in Patients with Breast Cancer Dormancy. *Clin Cancer Res* **10**: 8152–8162.
- Méndez-Ferrer S, Lucas D, Battista M, Frenette PS. 2008. Haematopoietic stem cell release is regulated by circadian oscillations. *Nature* **452**: 442–447.
- Miles FL, Sikes RA. 2014. Insidious Changes in Stromal Matrix Fuel Cancer Progression. *Molecular Cancer Research* **12**: 297–312.

- Mizoguchi F, Izu Y, Hayata T, Hemmi H, Nakashima K, Nakamura T, Kato S, Miyasaka N, Ezura Y, Noda M. 2010. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. *J Cell Biochem* **109**: 866–875.
- Morgan SC, Dearnaley DP. 2014. Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence? *Expert Review of Anticancer Therapy* **9**: 939–951.
- Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL. 2009. Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence. *Clinical cancer an* **15**(2):677–83.
- Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, et al. 2008. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. *Clinical & experimental metastasis* **25**: 377–388.
- Mueller MM, Fusenig NE. 2004. Friends or foes — bipolar effects of the tumour stroma in cancer. *Nat Rev Cancer* **4**: 839–849.
- Mundy GR. 2002. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer* **2**: 584–593.
- Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, Mettlin C. 1982. The national survey of prostate cancer in the United States by the American College of Surgeons. *J Urol* **127**: 928–934.
- Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, Eschenbach von AC, et al. 1997. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. *Clin Cancer Res* **3**: 2493–2500.
- Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, Park S-Y, Lu J, Protopopov A, Silberstein LE. 2013. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. *Nature Cell Biology* **15**: 533–543.
- Nowell P. 1976. The clonal evolution of tumor cell populations. *Science* **194**: 23–28.
- Ocaña OH, Córcoles R, Fabra Á, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. 2012. Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1. *Cancer Cell* **22**: 709–724.
- Ottewill PD, Wang N, Meek J, Fowles CA, Croucher PJ, Eaton CL, Holen I. 2014. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. *Endocr Relat Cancer* **21**: 769–781.
- Özdemir BC, Hensel J, Secondini C, Wetterwald A, Schwaninger R, Fleischmann A, Raffelsberger W, Poch O, Delorenzi M, Temanni R, et al. 2014. The Molecular Signature of the Stroma Response in Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion of Hematopoietic and Prostate Epithelial Stem Cell Niches ed. A. Angelucci. *PLoS ONE* **9**: e114530–32.
- Palmgren JS, Karavadia SS, Wakefield MR. 2007 Unusual and Underappreciated: Small Cell Carcinoma of the Prostate. *Seminars in oncology* **34**: 22–29.
- Pantel K, Speicher MR. 2015. The biology of circulating tumor cells. *Oncogene* **35**: 1216–1224.
- Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP. 1991. Transplantation of human prostatic carcinoma into nude mice in Matrigel. *Cancer Research* **51**: 3814–3817.
- Price TT, Burness ML, Sivan A, Warner MJ, Cheng R, Lee CH, Olivere L, Comatas K, Magnani J, Kim Lyerly H, et al. 2016. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. *Sci Transl Med* **8**: 340ra73.
- Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, et al. 2010. CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation. *Cancer Cell* **18**: 485–498.
- Rentsch CA, Cecchini MG, Thalmann GN. 2009. Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer. *Swiss Med Wkly* **139**: 220–225.
- Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, et al. 2011. Advancing a clinically relevant perspective of the clonal nature of cancer. *Proceedings of the National Academy of Sciences of the United States of America* **108**: 12054–12059.
- Sankineni S, Brown AM, Fascelli M, Law YM, Pinto PA, Choyke PL, Turkbey B. 2015. Lymph Node Staging in Prostate Cancer. *Current Urology Reports* **16**: 30.
- Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. 1995. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. *Cancer Research* **55**: 3551–3557.
- Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, Polzer B, Petronio M, Eils R, Klein CA. 2005. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. *Cancer Cell* **8**: 227–239.
- Scherr DS, Vaughan ED, Wei J, Chung M, Felsen D, Allbright R, Knudsen BS. 1999. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. *J Urol* **162**: 12–17.
- Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. 2005. Bone Turnover Mediates Preferential Localization of Prostate Cancer in the Skeleton. *Endocrinology* **146**: 1727–1736.

- Schneider JG, Amend SR, Weilbaecher KN. 2011. Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions. *Skeletal Complications of Cancer* **48**: 54–65.
- Schwanninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, van der Pluijm G, Löwik CWGM, Ackermann K, Pyerin W, Hamdy FC, et al. 2007. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. *Am J Pathol* **170**: 160–175.
- Secondini C, Wetterwald A, Schwanninger R, Thalmann GN, Cecchini MG. 2011. The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis. *PLoS ONE* **6**: e16078.
- Semenov M, Tamai K, He X. 2005. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. *Journal of Biological Chemistry* **280**: 26770–26775.
- Sherwood LM, Parris EE, Folkman J. 1971. Tumor Angiogenesis: Therapeutic Implications. *N Engl J Med* **285**: 1182–1186.
- Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, Yoon HJ, Parsana P, Mehra R, Wang J, et al. 2016. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. *Oncotarget* **7**: 41217–41232.
- Shiozawa Y, Pienta KJ, Taichman RS. 2011. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. *Clin Cancer Res* **17**: 5553–5558.
- Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics, 2014. *CA: A Cancer Journal for Clinicians* **64**: 9–29.
- Sleeman J, Steeg PS. 2010. Cancer metastasis as a therapeutic target. *Stopping Cancer in its Tracks: Metastasis as a Therapeutic Target* **46**: 1177–1180.
- Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TLJ, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, et al. 2009. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. *N Engl J Med* **361**: 745–755.
- Sterling JA, Edwards JR, Martin TJ, Mundy GR. 2011. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. *Bone*.
- Sugatani T, Hruska KA. 2009. Impaired micro-RNA pathways diminish osteoclast differentiation and function. *Journal of Biological Chemistry* **284**: 4667–4678.
- Sugatani T, Vacher J, Hruska KA. 2011. A microRNA expression signature of osteoclastogenesis. *Blood* **117**: 3648–3657.
- Sun Y-X, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, et al. 2004. Skeletal Localization and Neutralization of the SDF-1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo. *Journal of Bone and Mineral Research* **20**: 318–329.
- Thalgott M, Rack B, Horn T, Heck Mm, Eiber M, Kübler H, Retz M, Gschwend Je, Andergassen U, Nawroth R. 2015. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy. *Anticancer research* **35**: 5679–5685.
- Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LWK. 1999. Osteopontin: Possible Role in Prostate Cancer Progression. *Clin Cancer Res* **5**: 2271.
- Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. 2000. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. *Prostate* **44**: 91–103 Jul 1–44(2).
- Theriault RL. 2012. Biology of bone metastases. *Cancer Control* **19**: 92–101.
- Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. *Nat Rev Cancer* **2**: 442–454.
- Kakhki VR¹, Anvari K, Sadeghi R, Mahmoudian AS, Torabian-Kakhki M.. 2013. *Pattern and distribution of bone metastases in common malignant tumors*: Nucl Med Rev Cent East Eur. 2013;16(2):66-9.
- Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma Metastasis. *Cancer Cell* **22**: 725–736.
- Valastyan S, Weinberg RA. 2011. Tumor Metastasis: Molecular Insights and Evolving Paradigms. *Cell* **147**: 275–292.
- van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, et al. 2010. High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. *Cancer Research* **70**: 5163–5173.
- van der Pluijm G. 2011. Epithelial plasticity, cancer stem cells and bone metastasis formation. *Bone* **48**: 37–43.
- van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A, Thalmann GN, Papapoulos SE, Cecchini MG. 2005. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. *Cancer Research* **65**: 7682–7690.
- van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schröder FH, van Steenbrugge GJ. 1996. Development of seven new human prostate tumor xenograft models and their histopathological characterization. *Am J Pathol* **149**: 1055–1062.
- van Weerden WM, Romijn JC. 2000. Use of nude mouse xenograft models in prostate cancer research. *Prostate* **43**: 263–271.
- Vanharanta S, Massagué J. 2013. Origins of Metastatic Traits. *Cancer Cell* **24**: 410–421.

- Wang G, Wang J, Sadar MD. 2008. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. *Cancer Res* **68**: 9918–9927.
- Wang X, Julio MK-D, Economides KD, Walker D, Yu H, Halili MV, Hu Y-P, Price SM, Abate-Shen C, Shen MM. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer. *Nature* **461**: 495–500.
- Weilbaecher KN, Guise TA, McCauley LK. 2011. Cancer to bone: a fatal attraction. *Nat Rev Cancer* **11**: 411–425.
- Xiao Y, Woo WM, Nagao K, Li W, Terunuma A, Mukoyama YS, Oro AE, Vogel JC, Brownell I. 2013. Perivascular hair follicle stem cells associate with a venule annulus. *J Invest Dermatol* **133**: 2324–2331.
- Yang J, Weinberg RA. 2008. Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis. *Developmental cell* **14**: 818–829.
- Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. 2006. Bisphosphonates for advanced prostate cancer. *Cochrane Database Syst Rev* CD006250.
- Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L. 2005. Expression patterns of potential therapeutic targets in prostate cancer. *Int J Cancer* **113**: 619–628.
- Zhang J, Niu C, Ye L, Huang H, He X, Tong W-G, Ross J, Haug J, Johnson T, Feng JQ, et al. 2003. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* **425**: 836–841.
- Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clézardin P. 2007. Tumor v 3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases. *Cancer Research* **67**: 5821–5830.
- Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu C-C, LeBleu VS, Kalluri R. 2015. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature* **527**: 525–530.